XML 59 R38.htm IDEA: XBRL DOCUMENT v3.23.2
Collaborative and Other Relationships (Tables)
 6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Co-promotion profit sharing formula As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0 million varies upon the following events, as summarized in the table below:
After LUNSUMIO Approval until the First Threshold Date37.5 %
After First Threshold Date until the Second Threshold Date35.0 %
After Second Threshold Date30.0 %
Pretax profit sharing formula Our share of annual co-promotion profits in excess of $50.0 million varies upon the following events, as summarized in the table below:
Until Second GAZYVA Threshold Date37.5 %
After Second GAZYVA Threshold Date35.0 %
Revenues from anti-CD20 therapeutic programs
Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
 For the Three Months Ended June 30,For the Six Months Ended June 30,
(In millions)2023202220232022
Royalty revenue on sales of OCREVUS$325.5 $291.8 $609.1 $544.1 
Biogen’s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO(1)
103.6 139.9 216.1 283.1 
Other revenue from anti-CD20 therapeutic programs4.3 4.6 7.7 8.5 
Total revenue from anti-CD20 therapeutic programs$433.4 $436.3 $832.9 $835.7 
(1) LUNSUMIO became commercially available in the U.S. during the first quarter of 2023.
Summary of activity related to Aducanumab collaboration
A summary of development expense and sales and marketing expense related to our initial ADUHELM Collaboration Agreement is as follows:
For the Three Months Ended June 30,For the Six Months Ended June 30,
(In millions)20222022
Total ADUHELM Collaboration development expense$37.2 $81.4 
Biogen's share of ADUHELM Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income20.5 44.8 
Total sales and marketing expense incurred by the ADUHELM Collaboration Agreement40.8 135.8 
Biogen's share of ADUHELM Collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income21.1 72.0 
Summary of activity related to the UCB collaboration
A summary of development expense related to the UCB collaboration agreement is as follows:
For the Three Months Ended June 30,For the Six Months Ended June 30,
(In millions)2023202220232022
Total UCB collaboration development expense$14.3 $15.6 $32.6 $33.2 
Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income7.1 7.8 16.3 16.6 
Summary of Activity Related to Denali Therapeutics Collaboration
A summary of development expense related to the Denali collaboration is as follows:
For the Three Months Ended June 30,For the Six Months Ended June 30,
(In millions)2023202220232022
Total Denali collaboration development expense$22.1 $23.2 $38.7 $38.1 
Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income13.2 13.2 23.2 22.1 
Summary of Activity Related to BAN2401 and Elenbecestat Collaboration
For the Three Months Ended June 30,For the Six Months Ended June 30,
(In millions)2023202220232022
Total development expense incurred by the collaboration related to the advancement of LEQEMBI$86.2 $78.6 $194.1 $155.6 
Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income43.0 39.3 97.0 77.8 
Total sales and marketing expense incurred by the LEQEMBI Collaboration prior to commercialization(1)
17.1 23.4 27.6 39.3 
Biogen's share of the LEQEMBI Collaboration sales and marketing expense prior to commercialization reflected in selling, general and administrative expense in our condensed consolidated statements of income(1)
8.5 11.7 13.8 19.7 
(1) Beginning in the first quarter of 2023 reimbursement to Eisai for our portion of the profit share is recognized in revenue from LEQEMBI Collaboration within our condensed consolidated statements of income.
Summary of Activity Related to Sage Therapeutics
A summary of development and sales and marketing expense related to the Sage collaboration is as follows:
For the Three Months Ended June 30,For the Six Months Ended June 30,
(In millions)2023202220232022
Total Sage collaboration development expense$52.1 $50.8 $86.9 $89.5 
Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income26.1 25.3 43.5 44.7 
Total sales and marketing expense incurred by the Sage collaboration60.1 23.0 98.3 41.4 
Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income30.0 11.5 49.1 20.7